Jill Andersen Sells 49,402 Shares of Invivyd (NASDAQ:IVVD) Stock

Key Points

• Jill Andersen, an insider at Invivyd, Inc., sold 49,402 shares at an average price of $0.57, decreasing her position by 36.91%.
• Invivyd reported a loss of ($0.12) earnings per share for the last quarter, missing analysts' expectations and generating revenue of $11.79 million, which was below forecasted figures.
• Despite recent stock performance, analysts maintain an average rating of "Buy" for Invivyd, with target prices varying from $3.00 to $5.00.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Jill Andersen sold 49,402 shares of the company's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $28,159.14. Following the completion of the transaction, the insider directly owned 84,446 shares in the company, valued at $48,134.22. The trade was a 36.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jill Andersen also recently made the following trade(s):

• On Monday, August 18th, Jill Andersen sold 33,352 shares of Invivyd stock. The shares were sold at an average price of $0.65, for a total value of $21,678.80.

Invivyd Stock Down 1.7%

NASDAQ IVVD traded down $0.0101 on Tuesday, reaching $0.5710. The stock had a trading volume of 1,690,635 shares, compared to its average volume of 850,421. The firm has a market capitalization of $68.60 million, a price-to-earnings ratio of -0.62 and a beta of 0.51. Invivyd, Inc. has a 12-month low of $0.3546 and a 12-month high of $2.74. The stock has a fifty day moving average price of $0.75 and a two-hundred day moving average price of $0.84.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). The firm had revenue of $11.79 million during the quarter, compared to analysts' expectations of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. Sell-side analysts forecast that Invivyd, Inc. will post -1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on IVVD shares. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Invivyd in a research report on Thursday, June 26th. D. Boral Capital dropped their target price on Invivyd from $9.00 to $3.00 and set a "buy" rating for the company in a research report on Friday. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $3.85.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently bought and sold shares of the stock. 683 Capital Management LLC raised its position in Invivyd by 2.3% in the 2nd quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock valued at $2,195,000 after purchasing an additional 70,000 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Invivyd during the 2nd quarter worth about $147,000. Marshall Wace LLP acquired a new position in shares of Invivyd during the 2nd quarter worth about $158,000. Invesco Ltd. boosted its position in shares of Invivyd by 25.5% during the 2nd quarter. Invesco Ltd. now owns 136,755 shares of the company's stock worth $98,000 after acquiring an additional 27,756 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd acquired a new position in shares of Invivyd during the 2nd quarter worth about $27,000. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.